Lifecode Raises $20.5M For Molecular Diagnostics
Foster City-based Lifecode, a developer of gene sequencing-based molecular diagnostics products, said last week that it has raised $20.5M in a funding round. The funding was led by Sequoia Capital, the Mayo Clinic, and Mayo Ventures. Lifecode uses gene sequencing for analyzing cancer tumors. The company is led by Chris Rivest, and was--until January--known as Silicon Valley Biosystems (SV Bio). The company is initially focused on developing a gene-sequencing based cancer assay panels.
posted on Monday, February 23, 2015
Related companies:
Lifecode
Related stories:
> DiaCarta Gets $8M For Molecular Diagnostics
> Two Pore Guys Gains $24.5M For Molecular Diagnostics
> Veracyte Gets $28M In Series C For Molecular Diagnostics Products
> VitaPath Genetics Gets $6M
> Pathwork Diagnostics Raises $20M
silicontap.com Home